With over 30 years of experience in the US generic pharmaceutical market, we provide unparalleled experience to our partners. Our partners benefit from our well-established reputation for quality, compliance and customer service.
Strategic partnerships are an integral component of the Company's growth strategy. We are focused on developing products with limited competition, significant barriers to entry and longer life cycles. We continue to build and foster strategic business alliances with major pharmaceutical companies, specialty drug delivery companies and other product and service providers.
Achieving a successful partnership can present a number of challenges for many pharmaceutical companies. However, Par Pharmaceutical’s nimble organizational structure promotes decisive action and first-to-market status, helping to make partnerships run more smoothly and become successful more quickly.
Among the industry-differentiating qualities Par Pharmaceutical brings to every partnership collaboration:
- Collaborative culture and active involvement of key decision-makers early in the process
- Business development, licensing and legal expertise
- Sophisticated in-licensing and intellectual property teams
- Efficient launch execution with supportive distribution programs
- Strong distribution relationships with top US retail chains, wholesalers, distributors, managed care organizations, mail order pharmacies and Group Purchasing Organizations (GPOs)
We have been the authorized generic partner of choice for over 10 years for innovator companies and brand product marketers. We offer high-quality, highly complementary, US-based contract manufacturing services, and look for drug delivery expertise and an understanding of US generic requirements in our partners.
For specialty generic pharmaceutical product development companies, we use a variety of deal structures, ranging from fee-for-service to profit-sharing collaborations. Our portfolio and new-product partnering strategy is focused on first-to-file opportunities as well as challenging products with unusual barriers to entry.
We are interested in modified-release oral solid dosage forms as well as non-oral dosage forms such as nasal sprays, dry powder inhalers, patches and other alternative drug delivery platforms. Our focus is on Therapeutically Equivalent ANDA-based products, and others on a case-by-case basis.
For information regarding strategic partnerships, please contact
of our Business Development team.